17 Aug COVID-19 Vaccine Janssen
Posted at 11:50h
in
Janssen Pharmaceutica (Pty) Ltd, as directed by the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about new safety information that has resulted in contraindication of the COVID-19 Vaccine Janssen in individuals with a history of Capillary Leak Syndrome (CLS).
2021 Jul
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
23/07/2021
File Type:
pdf
Category:
Communication To Health Care Professionals